Copyright © 2008 Published by Elsevier Masson SAS
Entendu et noté
11e réunion internationale sur le myélome, 25–30 juillet 2007, île de Kos, Grèce
Results. – Acute toxicity was marked and included WHO grade III/IV mucositis (89%, 16%of them being grade IV), WHO grade III dermatitis (72%) and grade III/IV neutropenia (61%). This toxicity was significant but manageable with optimised supportive care, and never led to interruption of treatment for more than 1 week, although there were two toxic deaths. Complete global response rate at 6 months was 74%. Overall global survival at 1 and 2 years was 72%and 50%respectively, with a median follow-up of 17 months. Prognostic factors for overall survival were the Karnofsky index (71%survival at 3 years for patients with a Karnofsky index of 90–100%versus 30%for patients with a Karnofsky index of 80%versus 0%for patients with a Karnofsky index of 60-70%, p = 0.0001) and tumor location (55%at 3 years for oropharynx versus 37%for panpharynx versus 28%for hypopharynx, p = 0.009).
Conclusion. – These results confirm the efficacy of concomitant bid radiotherapy and chemotherapy in advanced unresectable tumor of the pharynx. The improvement in results will essentially depend on our capacity to restore in a good nutritional status the patients before beginning this heavy treatment.
Les nouveaux medicaments du myelome La Revue de Medecine Interne |
Les nouveaux médicaments du myélome La Revue de Médecine Interne, Volume 28, Issue 10, October 2007, Pages 682-688 C. Hulin Abstract RésuméProposAprès des décennies de progrès minimes, deux nouvelles classes médicamenteuses avec de nouveaux mécanismes d'action : immunomodulateurs (thalidomide et lénalidomide) et inhibiteur du protéasome (bortézomib), ont montré une grande efficacité dans le traitement du myélome multiple. |
View More Related Articles |
11e réunion internationale sur le myélome, 25–30 juillet 2007, île de Kos, Grèce